Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GlaxoSmithKline PLC Director's Dealing 2018

Jan 2, 2018

5262_dirs_2018-01-02_b524cf69-25ba-48b7-a06a-34c17b6a2832.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7425A

GlaxoSmithKline PLC

02 January 2018

GlaxoSmithKline plc (the "Company")

Director Shareholding

Further to the announcement made by the Company on 8 November 2017, in respect of the appointment of Dr Hal Barron as Chief Scientific Officer and President, R&D, and Executive Director, Dr Barron assumed his new role on 1 January 2018.

As at the date of his appointment to the Board, Dr Barron held 1,644 American Depositary Shares in the Company.

V A Whyte

Company Secretary

2 January 2018

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBTMJTMBAMBPP